NZ524936A - Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor - Google Patents
Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitorInfo
- Publication number
- NZ524936A NZ524936A NZ524936A NZ52493601A NZ524936A NZ 524936 A NZ524936 A NZ 524936A NZ 524936 A NZ524936 A NZ 524936A NZ 52493601 A NZ52493601 A NZ 52493601A NZ 524936 A NZ524936 A NZ 524936A
- Authority
- NZ
- New Zealand
- Prior art keywords
- inhibitor
- tyrosine kinase
- ftp
- methods
- cancer cell
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000004611 cancer cell death Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 208000032612 Glial tumor Diseases 0.000 abstract 1
- 206010018338 Glioma Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23824000P | 2000-10-05 | 2000-10-05 | |
| PCT/US2001/042509 WO2002028381A2 (en) | 2000-10-05 | 2001-10-05 | Methods of inducing cancer cell death and tumor regression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ524936A true NZ524936A (en) | 2005-08-26 |
Family
ID=22897049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ524936A NZ524936A (en) | 2000-10-05 | 2001-10-05 | Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6777415B2 (enExample) |
| EP (1) | EP1322334A2 (enExample) |
| JP (1) | JP2004510733A (enExample) |
| CN (1) | CN1479630A (enExample) |
| AU (2) | AU2002211862B2 (enExample) |
| BR (1) | BR0114430A (enExample) |
| CA (1) | CA2424797C (enExample) |
| HK (1) | HK1052870A1 (enExample) |
| HU (1) | HUP0302913A3 (enExample) |
| MX (1) | MXPA03003011A (enExample) |
| NO (1) | NO20031531L (enExample) |
| NZ (1) | NZ524936A (enExample) |
| WO (1) | WO2002028381A2 (enExample) |
| ZA (1) | ZA200302523B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6369138B2 (en) | 1997-07-11 | 2002-04-09 | Bridgestone Corporation | Processability of silica-filled rubber stocks with reduced hysteresis |
| WO2008109417A1 (en) * | 2007-03-02 | 2008-09-12 | Case Western Reserve University | Mgmt inhibitor combinations for the treatment of neoplastic disorders |
| WO2002028409A2 (en) * | 2000-10-05 | 2002-04-11 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
| US20040126755A1 (en) * | 2001-08-29 | 2004-07-01 | Stephan Dietrich A | Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs |
| CN1617755A (zh) * | 2001-11-30 | 2005-05-18 | 先灵公司 | 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用 |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| AU2003228225B2 (en) * | 2002-03-01 | 2010-05-13 | Roger Williams Hospital | SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer |
| US20050004008A1 (en) * | 2002-03-01 | 2005-01-06 | Frackelton A. Raymond | SHC proteins as therapeutic targets in proliferative diseases |
| US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
| US7691905B2 (en) * | 2002-12-24 | 2010-04-06 | New York University | Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA) |
| CA2544421A1 (en) * | 2003-11-06 | 2005-05-26 | Schering Corporation | Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| US20060205810A1 (en) * | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| US20070148660A1 (en) * | 2005-06-16 | 2007-06-28 | The Regents Of The University Of California | Treatment of maladaptive substance use with H-ras antagonists |
| JP2009511450A (ja) * | 2005-10-07 | 2009-03-19 | ノバルティス アクチエンゲゼルシャフト | ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ |
| WO2007058965A1 (en) * | 2005-11-11 | 2007-05-24 | Roger Williams Hospital | P66-shc as predictive marker in cancer treatment |
| CN102274513B (zh) * | 2011-07-06 | 2013-02-20 | 南开大学 | ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长 |
| CN102626416B (zh) * | 2012-05-11 | 2013-04-17 | 江苏省人民医院 | 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2098198A1 (en) | 1990-12-18 | 1992-06-18 | Ann Christie King | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
| EP0906099A4 (en) | 1996-04-03 | 2001-02-07 | Merck & Co Inc | METHOD FOR TREATING CANCER |
| JP2000508335A (ja) * | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | 癌の治療方法 |
| CN1267291A (zh) | 1997-06-17 | 2000-09-20 | 先灵公司 | 新的n－取代的脲的法呢基蛋白转移酶抑制剂 |
| ATE218137T1 (de) * | 1997-06-17 | 2002-06-15 | Schering Corp | Benzo(5,6)cyclohepta(1,2-b)pyridin derivate als farnesyl protein transferase inhibitoren |
| US6096757A (en) | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| AU779008C (en) | 1999-01-11 | 2005-06-30 | Princeton University | High affinity inhibitors for target validation and uses thereof |
| US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
| EP1181013B1 (en) * | 1999-04-14 | 2006-10-11 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
| US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
| WO2002000024A1 (en) * | 2000-06-30 | 2002-01-03 | The Regents Of The University Of California | New strategy for leukemia therapy |
| WO2002028409A2 (en) * | 2000-10-05 | 2002-04-11 | Whitehead Institute For Biomedical Research | Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors |
-
2001
- 2001-10-05 MX MXPA03003011A patent/MXPA03003011A/es active IP Right Grant
- 2001-10-05 HU HU0302913A patent/HUP0302913A3/hu unknown
- 2001-10-05 NZ NZ524936A patent/NZ524936A/xx unknown
- 2001-10-05 AU AU2002211862A patent/AU2002211862B2/en not_active Ceased
- 2001-10-05 HK HK03105046.0A patent/HK1052870A1/zh unknown
- 2001-10-05 AU AU1186202A patent/AU1186202A/xx active Pending
- 2001-10-05 EP EP01979952A patent/EP1322334A2/en not_active Withdrawn
- 2001-10-05 WO PCT/US2001/042509 patent/WO2002028381A2/en not_active Ceased
- 2001-10-05 CA CA002424797A patent/CA2424797C/en not_active Expired - Fee Related
- 2001-10-05 BR BR0114430-8A patent/BR0114430A/pt not_active IP Right Cessation
- 2001-10-05 CN CNA018201032A patent/CN1479630A/zh active Pending
- 2001-10-05 JP JP2002532206A patent/JP2004510733A/ja active Pending
- 2001-10-05 US US09/971,545 patent/US6777415B2/en not_active Expired - Fee Related
-
2003
- 2003-03-31 ZA ZA200302523A patent/ZA200302523B/en unknown
- 2003-04-04 NO NO20031531A patent/NO20031531L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU1186202A (en) | 2002-04-15 |
| US6777415B2 (en) | 2004-08-17 |
| CA2424797C (en) | 2009-12-29 |
| HUP0302913A3 (en) | 2005-05-30 |
| AU2002211862B2 (en) | 2007-03-15 |
| NO20031531D0 (no) | 2003-04-04 |
| ZA200302523B (en) | 2004-08-24 |
| MXPA03003011A (es) | 2003-07-14 |
| WO2002028381A2 (en) | 2002-04-11 |
| HUP0302913A2 (hu) | 2003-12-29 |
| US20020128280A1 (en) | 2002-09-12 |
| BR0114430A (pt) | 2004-01-06 |
| NO20031531L (no) | 2003-06-05 |
| JP2004510733A (ja) | 2004-04-08 |
| HK1052870A1 (zh) | 2003-10-03 |
| EP1322334A2 (en) | 2003-07-02 |
| WO2002028381A3 (en) | 2003-03-27 |
| CN1479630A (zh) | 2004-03-03 |
| CA2424797A1 (en) | 2002-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ524936A (en) | Methods of inducing cancer cell death and tumor regression using a FTP inhibitor and a tyrosine kinase inhibitor | |
| EE200300475A (et) | Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis | |
| JO2373B1 (en) | W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors | |
| WO1999057117A3 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
| WO2006004833A3 (en) | Pyrrolotriazine kinase inhibitors | |
| ZA200108258B (en) | Methods of inducing cancer cell death and tumor regression. | |
| MXPA04003668A (es) | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. | |
| WO2003049702A3 (en) | Vanilloid receptor ligands and their use in treatments | |
| MXPA05004919A (es) | Composicion farmaceutica que comprende un inhibidor cdk y gemcitabina. | |
| IL155367A0 (en) | NOVEL 2,4,8-TRISUBSTITUTED-8h-PYRIDO[2,3,-d]PYRIMIDIN-7-ONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, PROCESSES FOR THE PREPARATION THEREOF, AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING CSBP/p38 KINASE MEDIATED DISEASES | |
| EP1158985A4 (en) | GAMMA CARBOXYARYL SUBSTITUTED DIPHENYL HARVESE COMPOUNDS AS p38 KINASE HEMMER | |
| MY142019A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| GB0121490D0 (en) | Ciompounds | |
| AR035450A1 (es) | Combinaciones antineoplasicas, el uso de dichas combinaciones para la preparacion de un medicamento, un producto que comprende dicha combinacion | |
| EA200400235A1 (ru) | Комбинированная терапия для лечения рака | |
| TR200401316T4 (tr) | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler | |
| NO20024076L (no) | Sammensetning omfattende camptotecin og et pyrimidinderivat for behandling av cancer | |
| DE60115466D1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
| MXPA02010759A (es) | Derivados del acido (2-oxindol-3-ilidenil) acetico y su uso como inhibidores de la proteina quinasa. | |
| TR200101693T2 (tr) | Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi. | |
| GB0121494D0 (en) | Compounds | |
| ATE381568T1 (de) | Pyrano(2,3-c)imidazo(1,2-a)pyridin-derivate zur behandlung von gastrointestinalen erkrankungen | |
| TR200302134T4 (tr) | 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RENW | Renewal (renewal fees accepted) | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |